DS 1515
Alternative Names: DS-1515Latest Information Update: 28 Oct 2022
At a glance
- Originator Daiichi Sankyo Company
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- No development reported Asthma; Inflammation